Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.47 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | APEX1 | P27695 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29257673 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| SCHEMBL9354169 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| Hydrochloric Acid SCHEMBL31544055 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| SCHEMBL9136499 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| Hydrochloric Acid SCHEMBL23607552 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| Hydrochloric Acid SCHEMBL23607540 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| Hydrochloric Acid SCHEMBL31544038 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| Hydrochloric Acid SCHEMBL9130302 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| Hydrochloric Acid SCHEMBL6403357 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 | |
| SCHEMBL27552592 | 1.00 | TSHR (0.65) | TSHRAPEX1POLBHTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0708103-B1 | Process for the preparation of a tetrazole derivative in two crystalline forms and a new crystalline form of this derivative | SANOFI SYNTHELABO (FR) | 2001-01-03 | — | — | EP | claimed |
| US-5629331-A | 2-BUTYL-3-TETRAZOLYLBIPHENYLYLMETHYL-1,3-DIAZASPIRONONENONE MADE BY REACTING CORRESPONDING NITRILE WITH ALKALINE AZIDE AND TRIETHYLAMINE HYDROCHLORIDE IN INERT POLAR APROTIC SOLVENT, NEUTRALIZING SALT, CRYSTALLIZING IN ONE OF TWO WAYS | SANOFI (FR) | 1997-05-13 | — | — | US | claimed |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | HETERO LABS LIMITED (IN) | 2023-05-23 | — | — | US | disclosed |
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | HETERO LABS LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| EP-1285947-B1 | ANTIMICROBIAL COMPOSITION | KURARAY CO (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20050176793-A1 | Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one | DR. REDDY' LABORATORIES LTD. | 2005-08-11 | — | — | US | disclosed |
| US-20030064102-A1 | Antimicrobial Composition | NAKATSUKA KAZUMITSU (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1285947-A1 | ANTIMICROBIAL COMPOSITION | KURARAY CO., LTD. (JP) | 2003-02-26 | — | — | EP | disclosed |
| US-20020198284-A1 | Adhesive composition | KURARAY CO. LTD, (JP) | 2002-12-26 | — | — | US | disclosed |
| US-5629331-A | 2-BUTYL-3-TETRAZOLYLBIPHENYLYLMETHYL-1,3-DIAZASPIRONONENONE MADE BY REACTING CORRESPONDING NITRILE WITH ALKALINE AZIDE AND TRIETHYLAMINE HYDROCHLORIDE IN INERT POLAR APROTIC SOLVENT, NEUTRALIZING SALT, CRYSTALLIZING IN ONE OF TWO WAYS | SANOFI (FR) | 1997-05-13 | — | — | US | disclosed |
| US-5629331-A | 2-BUTYL-3-TETRAZOLYLBIPHENYLYLMETHYL-1,3-DIAZASPIRONONENONE MADE BY REACTING CORRESPONDING NITRILE WITH ALKALINE AZIDE AND TRIETHYLAMINE HYDROCHLORIDE IN INERT POLAR APROTIC SOLVENT, NEUTRALIZING SALT, CRYSTALLIZING IN ONE OF TWO WAYS | SANOFI (FR) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127238-A1 | PROCESS FOR THE PREPARATION OF ANGIOTENSIN II RECEPTOR BLOCKERS | AGTR2, AGTR1, ADRB1 | CHRM1 512/4885CHRM3 166/4885CHRM2 267/4885 |
| US-20050176793-A1 | Amorphous form of 2-n-butyl-3-((2-(1h-tetrazol-5-yl)([1,1'-biphenyl)-4-yl)methyl)-1, 3-diazaspiro(4,4')non-1-en-4-one | AGTR1, NPR1, AGTR2 | CHRM1 314/4885CHRM3 679/4885CHRM2 742/4885 |
| US-11655220-B2 | Process for the preparation of angiotensin II receptor blockers | AGTR2, AGTR1, ADRB1 | CHRM1 512/4885CHRM3 166/4885CHRM2 267/4885 |
| US-20030064102-A1 | Antimicrobial Composition | AAAS, H1-0, H1-10 | CHRM1 2857/4885CHRM3 4321/4885CHRM2 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.